Vasilis Babaliaros, MD
Interventional Cardiology · Atlanta, GANPI 1205884525
Payments from drug & device makers
Across 434 payments — averaging $6298.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$2.4M
- Abbott$236K
- Medtronic$72K
- Bayer$4K
- W. L. Gore & Associates, Inc.$829
- Boston Scientific$320
- plus $272 from 2 others
What the payments were for
- Consulting fees$7,10050%
- Travel & lodging$821%
- Food & beverage$7,15850%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 275 | $2,421,118 |
| Abbott | 104 | $235,657 |
| Medtronic(2 entities) | 30 | $71,694 |
| Bayer | 2 | $3,758 |
| W. L. Gore & Associates, Inc. | 15 | $829 |
| Boston Scientific | 6 | $320 |
| Abiomed | 1 | $150 |
| Shockwave Medical, Inc | 1 | $122 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Edwards SAPIEN 3 Transcatheter Heart Valve$4,868
- MitraClip System$2,500
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$455
- Mitra Clip system$296
- APOLLOTM$167
- COREVALVE EVOLUT R$154
- Impella$150
- CARDIOFORM Septal Occluder$137
- CoreValve Evolut$130
- OPTICROSS$128
- GORE CARDIOFORM Septal Occluder$122
- Vascular Lithotripsy$122
- MitraClip$113
- ONYX FRONTIER$107
How this compares
$2,733,646 in reported general payments places this provider in the 95th percentile of 218 interventional cardiology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 41 | $31,593 |
| Metoprolol Succinate | 18 | $302 |
| Atorvastatin Calcium | 12 | $128 |
| ClopidogrelClopidogrel Bisulfate | 19 | $102 |
| Furosemide | 20 | $39 |
| Amoxicillin | 12 | $14 |
| Clindamycin Hcl | 12 | $8 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Atlanta
- David KandzariAtlanta$3.7M
- Pradeep YadavAtlanta$3.5M
- William NicholsonAtlanta$2M
- Chandanreddy DevireddyAtlanta$1.9M
- Adam GreenbaumAtlanta$1.8M
- Vivek RajagopalAtlanta$1.3M
- Christopher MeduriAtlanta$1.1M
- Wissam JaberAtlanta$981K
- George HanzelAtlanta$750K
- Andrew KleinAtlanta$589K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.